Illumina, Inc. (NASDAQ:ILMN) SVP Charles Dadswell sold 145 shares of the company’s stock in a transaction dated Tuesday, October 3rd. The shares were sold at an average price of $202.23, for a total value of $29,323.35. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Charles Dadswell also recently made the following trade(s):

  • On Tuesday, September 5th, Charles Dadswell sold 145 shares of Illumina stock. The shares were sold at an average price of $205.71, for a total value of $29,827.95.
  • On Thursday, August 3rd, Charles Dadswell sold 1,609 shares of Illumina stock. The shares were sold at an average price of $197.00, for a total value of $316,973.00.

Shares of Illumina, Inc. (NASDAQ:ILMN) traded down 0.7943% during mid-day trading on Friday, hitting $204.1455. The stock had a trading volume of 320,107 shares. The stock’s 50-day moving average price is $202.20 and its 200-day moving average price is $184.09. The firm has a market cap of $29.81 billion, a PE ratio of 40.9602 and a beta of 0.76. Illumina, Inc. has a 52-week low of $119.37 and a 52-week high of $214.34.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Tuesday, August 1st. The life sciences company reported $0.82 EPS for the quarter, topping analysts’ consensus estimates of $0.68 by $0.14. Illumina had a return on equity of 19.69% and a net margin of 30.27%. The firm had revenue of $662.00 million for the quarter, compared to analysts’ expectations of $642.38 million. During the same period in the previous year, the firm posted $0.86 EPS. The business’s revenue for the quarter was up 10.3% compared to the same quarter last year. On average, analysts anticipate that Illumina, Inc. will post $3.65 earnings per share for the current fiscal year.

WARNING: This piece of content was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of US and international copyright law. The correct version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/10/06/illumina-inc-ilmn-svp-charles-dadswell-sells-145-shares.html.

Institutional investors and hedge funds have recently modified their holdings of the company. Paradigm Asset Management Co. LLC boosted its position in shares of Illumina by 5.6% in the 2nd quarter. Paradigm Asset Management Co. LLC now owns 950 shares of the life sciences company’s stock worth $165,000 after purchasing an additional 50 shares in the last quarter. Patriot Financial Group Insurance Agency LLC boosted its position in shares of Illumina by 1.4% in the 2nd quarter. Patriot Financial Group Insurance Agency LLC now owns 3,126 shares of the life sciences company’s stock worth $528,000 after purchasing an additional 43 shares in the last quarter. Cambridge Investment Research Advisors Inc. boosted its position in shares of Illumina by 298.7% in the 2nd quarter. Cambridge Investment Research Advisors Inc. now owns 10,447 shares of the life sciences company’s stock worth $1,813,000 after purchasing an additional 7,827 shares in the last quarter. Eagle Asset Management Inc. bought a new stake in shares of Illumina in the 2nd quarter worth approximately $27,175,000. Finally, Stephens Investment Management Group LLC boosted its position in shares of Illumina by 0.5% in the 2nd quarter. Stephens Investment Management Group LLC now owns 168,706 shares of the life sciences company’s stock worth $29,274,000 after purchasing an additional 803 shares in the last quarter. 93.32% of the stock is currently owned by hedge funds and other institutional investors.

A number of equities research analysts have commented on the company. First Analysis upgraded Illumina from an “underweight” rating to an “equal weight” rating and set a $176.00 price target on the stock in a research report on Wednesday, August 2nd. Zacks Investment Research lowered Illumina from a “buy” rating to a “hold” rating in a research report on Friday, August 4th. Barclays PLC reiterated an “equal weight” rating and issued a $150.00 price target on shares of Illumina in a research report on Wednesday, August 9th. Canaccord Genuity reiterated a “hold” rating and issued a $170.00 price target on shares of Illumina in a research report on Wednesday, July 26th. Finally, BidaskClub lowered Illumina from a “hold” rating to a “sell” rating in a research report on Thursday, August 17th. Three equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and eleven have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $183.00.

Illumina Company Profile

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Insider Buying and Selling by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Stock Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related stocks with our FREE daily email newsletter.